Free Trial
NASDAQ:RNAC

Cartesian Therapeutics (RNAC) Stock Price, News & Analysis

Cartesian Therapeutics logo
$11.18 -0.20 (-1.72%)
Closing price 07/3/2025 02:02 PM Eastern
Extended Trading
$11.15 -0.03 (-0.22%)
As of 07/3/2025 04:57 PM Eastern
Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more.

About Cartesian Therapeutics Stock (NASDAQ:RNAC)

Key Stats

Today's Range
$10.95
$11.53
50-Day Range
$8.77
$12.70
52-Week Range
$8.46
$26.50
Volume
52,381 shs
Average Volume
103,876 shs
Market Capitalization
$289.99 million
P/E Ratio
N/A
Dividend Yield
N/A
Price Target
$40.67
Consensus Rating
Moderate Buy

Company Overview

Cartesian Therapeutics Stock Analysis - MarketRank™

See Top-Rated MarketRank™ Stocks
29th Percentile Overall Score

RNAC MarketRank™: 

Cartesian Therapeutics scored higher than 29% of companies evaluated by MarketBeat, and ranked 785th out of 929 stocks in the medical sector. Scores are calculated by averaging available category scores, with extra weight given to analysis and valuation.

  • Consensus Rating

    Cartesian Therapeutics has received a consensus rating of Moderate Buy. The company's average rating score is 2.80, and is based on 4 buy ratings, 1 hold rating, and no sell ratings.

  • Amount of Analyst Coverage

    Cartesian Therapeutics has only been the subject of 2 research reports in the past 90 days.

  • Read more about Cartesian Therapeutics' stock forecast and price target.
  • Earnings Growth

    Earnings for Cartesian Therapeutics are expected to decrease in the coming year, from $4.56 to ($3.07) per share.

  • Price to Earnings Ratio vs. the Market

    The P/E ratio of Cartesian Therapeutics is -0.21, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.

  • Price to Earnings Ratio vs. Sector

    The P/E ratio of Cartesian Therapeutics is -0.21, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.

  • Read more about Cartesian Therapeutics' valuation and earnings.
  • Percentage of Shares Shorted

    31.65% of the float of Cartesian Therapeutics has been sold short.
  • Short Interest Ratio / Days to Cover

    Cartesian Therapeutics has a short interest ratio ("days to cover") of 31, which indicates bearish sentiment.
  • Change versus previous month

    Short interest in Cartesian Therapeutics has recently increased by 3.14%, indicating that investor sentiment is decreasing.
  • Dividend Yield

    Cartesian Therapeutics does not currently pay a dividend.

  • Dividend Growth

    Cartesian Therapeutics does not have a long track record of dividend growth.

  • Percentage of Shares Shorted

    31.65% of the float of Cartesian Therapeutics has been sold short.
  • Short Interest Ratio / Days to Cover

    Cartesian Therapeutics has a short interest ratio ("days to cover") of 31, which indicates bearish sentiment.
  • Change versus previous month

    Short interest in Cartesian Therapeutics has recently increased by 3.14%, indicating that investor sentiment is decreasing.
  • Search Interest

    1 people have searched for RNAC on MarketBeat in the last 30 days.
  • Insider Buying vs. Insider Selling

    In the past three months, Cartesian Therapeutics insiders have not sold or bought any company stock.

  • Percentage Held by Insiders

    60.30% of the stock of Cartesian Therapeutics is held by insiders. A high percentage of insider ownership can be a sign of company health.

  • Percentage Held by Institutions

    86.95% of the stock of Cartesian Therapeutics is held by institutions. High institutional ownership can be a signal of strong market trust in this company.

  • Read more about Cartesian Therapeutics' insider trading history.
Receive RNAC Stock News and Ratings via Email

Sign-up to receive the latest news and ratings for Cartesian Therapeutics and its competitors with MarketBeat's FREE daily newsletter.

RNAC Stock News Headlines

This Signal Only Flashes Once Every 4 Years – And It Just Triggered
This same signal has appeared twice before in the past 8 years — both times, it kicked off major moves in crypto. Now it’s back, and the smart money is already positioning. A free training reveals the step-by-step strategy and altcoin picks designed to help you capitalize on the next wave.
See More Headlines

RNAC Stock Analysis - Frequently Asked Questions

Cartesian Therapeutics' stock was trading at $17.91 at the beginning of 2025. Since then, RNAC shares have decreased by 37.6% and is now trading at $11.1750.

Cartesian Therapeutics, Inc. (NASDAQ:RNAC) announced its earnings results on Thursday, May, 8th. The company reported ($0.68) EPS for the quarter, missing the consensus estimate of ($0.61) by $0.07. The business had revenue of $1.10 million for the quarter, compared to analysts' expectations of $0.69 million.

Cartesian Therapeutics's stock reverse split before market open on Friday, April 5th 2024.The 1-30 reverse split was announced on Friday, April 5th 2024. The number of shares owned by shareholders was adjusted after the market closes on Friday, April 5th 2024. An investor that had 100 shares of stock prior to the reverse split would have 3 shares after the split.

Shares of RNAC stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Charles Schwab, E*TRADE, Fidelity, and Vanguard Brokerage Services.

Based on aggregate information from My MarketBeat watchlists, some other companies that Cartesian Therapeutics investors own include NVIDIA (NVDA), Advanced Micro Devices (AMD), Meta Platforms (META), Tesla (TSLA), Netflix (NFLX), JPMorgan Chase & Co. (JPM) and Alphabet (GOOG).

Company Calendar

Last Earnings
5/08/2025
Today
7/05/2025
Next Earnings (Estimated)
8/06/2025
Fiscal Year End
12/31/2025

Industry, Sector and Symbol

Stock Exchange
NASDAQ
Sector
Medical
Industry
MED - BIOMED/GENE
Sub-Industry
Pharmaceutical Products
Current Symbol
NASDAQ:RNAC
Previous Symbol
NASDAQ:RNAC
Employees
64
Year Founded
N/A

Price Target and Rating

Average Stock Price Target
$40.67
High Stock Price Target
$42.00
Low Stock Price Target
$40.00
Potential Upside/Downside
+263.9%
Consensus Rating
Moderate Buy
Rating Score (0-4)
2.80
Research Coverage
5 Analysts

Profitability

Trailing P/E Ratio
N/A
Forward P/E Ratio
2.45
P/E Growth
N/A
Net Income
-$77.42 million
Pretax Margin
-111.27%

Debt

Sales & Book Value

Annual Sales
$38.91 million
Price / Cash Flow
N/A
Book Value
($0.27) per share
Price / Book
-41.39

Miscellaneous

Free Float
10,304,000
Market Cap
$289.99 million
Optionable
Optionable
Beta
0.36
Beginner's Guide To Retirement Stocks Cover

Enter your email address and we'll send you MarketBeat's list of seven best retirement stocks and why they should be in your portfolio.

Get This Free Report

This page (NASDAQ:RNAC) was last updated on 7/5/2025 by MarketBeat.com Staff
From Our Partners